DVA — DaVita Inc.

The market is split. Q2 2026 EPS of $4.02 beat consensus by $0.14 and revenue of $3.554B beat by roughly $50M, but management only reaffirmed full-year guidance rather than raising it, disappointing the Street's aggressive estimates. The Humana integrated-kidney-care expansion on 8/25/2026 is a positive strategic signal, yet the analyst consensus is only Hold (10 buy / 12 hold / 1 sell) and the stock has slid from $247 to $179.

Revenue growth has been steady mid-single digit: Q2 2026 revenue of $3.554B was +5.2% YoY, Q1 2026 was +6.0% YoY, and Q3 2025 was +4.8%; Q4 2025's +9.9% spike looks like a one-off rather than the trend. Operating margin is stable: Q2 2026 was 16.1% vs 15.9% a year earlier, and TTM operating margin is 15.1%. Net income is lumpy (Q3 2025 was only $150M; Q2 2026 was $265M), but cash flow is healthy and improving — TTM free cash flow is about $1.61B, up roughly 25% from the prior TTM. This is a defensive grower with better cash conversion, not a cyclical trough or a deteriorating franchise.

As of 2026-08-27, the reported TTM P/E is 15.38, above the 5-year average of 12.79, but forward P/E on next-FY consensus EPS of $14.845 is only about 12.1x — below its own history. P/S of 0.82 is exactly the 5-year average, and PEG of 1.31 is not demanding. Given stable margins and strong FCF, the stock is fairly valued to modestly cheap on a forward basis. The high leverage and negative book equity ($765M) make balance-sheet multiples meaningless, but they justify keeping a cap on the multiple.

At $178.88, the market is pricing in caution, not collapse. If DaVita merely hits the next-FY EPS estimate of $14.845 and trades at its 5-year average P/E of 12.79, the stock is worth roughly $190. A modest re-rate to 14x gets to about $208. The Q2 beat without a guidance raise suggests management has built cushion into estimates; the bigger risk is that treatment-volume growth stays below the 2% target and analysts cut Q3/Q4 estimates, keeping the multiple capped.

As of 2026-08-27, RSI 14 is 32.71, close to oversold. Price is 4.64% below its 20-day SMA and 15.64% below its 50-day SMA, but still 10.19% above its 200-day SMA. That is a sharp pullback within a longer uptrend, not a breakdown through all timeframes. The nearest meaningful support is roughly the 200-day area near $162; a reclaim of the 20-day would be the first stabilization signal. This is not a momentum entry, but the risk/reward starts to improve in this oversold zone.

• Reimbursement dependence: roughly two-thirds of U.S. revenue is tied to government/Medicare frameworks, so CMS rate decisions and Medicare Advantage policy are the dominant swing factors.
• Interest rates and leverage: with about $10.66B of long-term debt and negative equity, rising rates or difficult refinancing conditions would pressure EPS; rate cuts would be an accelerant.
• Non-discretionary demand: ESRD/CKD treatment volumes are demographically driven and recession-resistant, giving the stock utility-like stability.
• Healthcare cost inflation: wage pressure for nurses/staff and supply costs can squeeze facility-level operating margins if not offset by rate increases.
• Value-based care transition: MA plans and IKC-style upstream CKD agreements could shift revenue from per-treatment to risk-based models, changing margin and volume sensitivity.

• Q3 2026 earnings in early November 2026 — updated treatment-volume trends and any full-year guidance change will likely set near-term direction.
• Scaling of the expanded Humana IKC value-based care agreement covering 10,000+ Medicare Advantage members with CKD stages 3B-5.
• Ongoing share repurchases at recent lower prices (2.2M shares at an average of $154.95 in Q2) can drive EPS even if revenue growth stays modest.
• A more benign reimbursement or interest-rate environment could remove a major overhang on the multiple.

• Medicare/Medicaid reimbursement cuts or unfavorable rate-setting would hit revenue and margins directly, given the government-payer mix.
• High financial leverage and negative stockholders' equity reduce financial flexibility; refinancing at higher rates would hurt earnings.
• Commercial insurance mix deterioration or ACA exchange policy changes could lower revenue per treatment.
• Value-based care execution risk: If IKC-style contracts produce higher costs before savings, near-term margins could compress.
• Dialysis volume growth staying below the long-term 2% target would make current consensus estimates look too high.

DaVita is fundamentally sound — stable mid-single-digit revenue growth, ~15% operating margins, negative accruals, and TTM FCF of ~$1.6B — and the stock has been knocked down to a forward P/E below its own history. For an investor willing to stomach reimbursement and leverage risk, this looks like an attractive entry point around $178.88. This is analysis, not personalized financial advice.

I calculated fair value by applying a 14.15x forward P/E to next-FY consensus EPS of $14.845 — a ~10% premium to DaVita's 5-year average P/E of 12.79, justified by better cash conversion and stable margins but capped by high leverage and negative book equity. That yields roughly $210, below the $235.67 consensus target.